Tazepam

Tazepam may be available in the countries listed below.

Ingredient matches for Tazepam

Oxazepam

Oxazepam is reported as an ingredient of Tazepam in the following countries:

• Georgia


• Latvia


• Lithuania


• Russian Federation

International Drug Name Search

Spiramycine Métronidazole Winthrop

Spiramycine Métronidazole Winthrop may be available in the countries listed below.

Ingredient matches for Spiramycine Métronidazole Winthrop

Metronidazole

Metronidazole is reported as an ingredient of Spiramycine Métronidazole Winthrop in the following countries:

• France

Spiramycin

Spiramycin is reported as an ingredient of Spiramycine Métronidazole Winthrop in the following countries:

• France

International Drug Name Search

Torasemide Sandoz

Torasemide Sandoz may be available in the countries listed below.

Ingredient matches for Torasemide Sandoz

Torasemide

Torasemide is reported as an ingredient of Torasemide Sandoz in the following countries:

• Belgium

International Drug Name Search

Bocouture

Bocouture may be available in the countries listed below.

Ingredient matches for Bocouture

Botulinum A Toxin

Botulinum A Toxin is reported as an ingredient of Bocouture in the following countries:

• Germany

International Drug Name Search

Ther

Ther may be available in the countries listed below.

Ingredient matches for Ther

Tegaserod

Tegaserod maleate (a derivative of Tegaserod) is reported as an ingredient of Ther in the following countries:

• Chile

International Drug Name Search

Diabetol

Diabetol may be available in the countries listed below.

Ingredient matches for Diabetol

Tolbutamide

Tolbutamide is reported as an ingredient of Diabetol in the following countries:

• Poland

International Drug Name Search

Nufatrac

Nufatrac may be available in the countries listed below.

Ingredient matches for Nufatrac

Itraconazole

Itraconazole is reported as an ingredient of Nufatrac in the following countries:

• Indonesia

International Drug Name Search

Gelatin

Scheme

NF

ATC (Anatomical Therapeutic Chemical Classification)

B05AA06

CAS registry number (Chemical Abstracts Service)

0009000-70-8

Therapeutic Categories

Pharmaceutic aid

Plasmaexpander

Hemostatic agent, local

Foreign Names

• Gelatina (Latin)
• Gelatine (German)
• Gélatine (French)
• Gelatina (Spanish)

Generic Names

• Gelatin (OS: JAN)
• UNII-2G86QN327L (IS)
• Gelatin (PH: Ph. Eur. 6, BP 2010, NF 27, Ph. Int. 4, JP XV)
• Gelatina (PH: Ph. Eur. 6, Ph. Int. 4)
• Gelatine (PH: Ph. Eur. 6)
• Purified Gelatin (PH: JP XV)
• Gelofusin (IS)
• Modified fluid gelatin (IS)
• Modifizierte Gelatine (IS)

Brand Names

• GEL-PHAN
  Pierre Fabre Dermatologie, France



• Gelafundin
  B.Braun, Germany



• Gelofusine
  B.Braun Medical, South Africa; Biomed, New Zealand; Braun, Australia; Braun, Estonia; Braun, Finland; Braun, Luxembourg; Braun, Myanmar; Braun, Sweden; Braun, Turkey; Braun Melsungen, Austria; Braun Melsungen-D, Italy; Medis, Slovenia

International Drug Name Search

Glossary

IS	Inofficial Synonym
JAN	Japanese Accepted Name
NF	The National Formulary (USA)
OS	Official Synonym
PH	Pharmacopoeia Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Terbinafin Nordic Drugs

Terbinafin Nordic Drugs may be available in the countries listed below.

Ingredient matches for Terbinafin Nordic Drugs

Terbinafine

Terbinafine hydrochloride (a derivative of Terbinafine) is reported as an ingredient of Terbinafin Nordic Drugs in the following countries:

• Denmark

International Drug Name Search

Neutraflux

Neutraflux may be available in the countries listed below.

Ingredient matches for Neutraflux

Domperidone

Domperidone is reported as an ingredient of Neutraflux in the following countries:

• India

Esomeprazole

Esomeprazole magnesium, trihydrate (a derivative of Esomeprazole) is reported as an ingredient of Neutraflux in the following countries:

• India

International Drug Name Search

Zetia

Zetia is a brand name of ezetimibe, approved by the FDA in the following formulation(s):

ZETIA (ezetimibe - tablet; oral)

• 
  Manufacturer: MSP SINGAPORE
  
  Approval date: October 25, 2002
  
  Strength(s): 10MG ^[RLD]

Has a generic version of Zetia been approved?

No. There is currently no therapeutically equivalent version of Zetia available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zetia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors
  Patent 5,846,966
  Issued: December 8, 1998
  Inventor(s): Rosenblum; Stuart B. & Dugar; Sundeep & Burnett; Duane A. & Clader; John W. & McKittrick; Brian A.
  Assignee(s): Schering Corporation
  Hydroxy-substituted azetidinone hypocholesterolemic agents of the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein: Ar.sup.1 and Ar.sup.2 are aryl or R.sup.4 -substituted aryl; Ar.sup.3 is aryl or R.sup.5 -substituted aryl; X, Y and Z are --CH.sub.2 --, --CH(lower alkyl)-- or --C(dilower alkyl)--; R and R.sup.2 are --OR.sup.6, --O(CO)R.sup.6, --O(CO)OR.sup.9 or --O(CO)NR.sup.6 R.sup.7 ; R.sup.1 and R.sup.3 are H or lower alkyl; q is 0 or 1; r is 0 or 1; m, n and p are 0-4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1-6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1-5; R.sup.4 is selected from lower alkyl, R.sup.5, --CF.sub.3, --CN, --NO.sub.2 and halogen; R.sup.5 is selected from --OR.sup.6, --O(CO)R.sup.6, --O(CO)OR.sup.9, --O(CH.sub.2).sub.1-5 OR.sup.6, --O(CO)NR.sup.6 R.sup.7, --NR.sup.6 R.sup.7, --NR.sup.6 (CO)R.sup.7, --NR.sup.6 (CO)OR.sup.9, --NR.sup.6 (CO)NR.sup.7 R.sup.8, --NR.sup.6 SO.sub.2 R.sup.9, --COOR.sup.6, --CONR.sup.6 R.sup.7, --COR.sup.6, --SO.sub.2 NR.sup.6 R.sup.7, S(O).sub.0-2 R.sup.9, --O(CH.sub.2).sub.1-10 --COOR.sup.6, --O(CH.sub.2).sub.1-10 CONR.sup.6 R.sup.7, --(lower alkylene)COOR.sup.6 and --CH.dbd.CH--COOR.sup.6 ; R.sup.6, R.sup.7 and R.sup.8 are H, lower alkyl, aryl or aryl-substituted lower alkyl; R.sup.9 is lower alkyl, aryl or aryl-substituted lower alkyl; are disclosed, as well as a method of lowering serum cholesterol by administering said compounds, alone or in combination with a cholesterol biosynthesis inhibitor, pharmaceutical compositions containing them, and a process for preparing them.
  
  Patent expiration dates:
  
  
  • September 21, 2013
    
    ✓ 
    Patent use: TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WIHT PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN
  
  
  
  • September 21, 2013
    
    ✓ 
    Patent use: TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
  
  
  
  • September 21, 2013
    
    ✓ 
    Patent use: TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN
  
  
  
  • March 21, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Sterol absorption inhibitor compositions
  Patent 7,030,106
  Issued: April 18, 2006
  Inventor(s): Cho; Wing-Kee Philip
  Assignee(s): Schering Corporation
  The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.
  
  Patent expiration dates:
  
  
  • January 25, 2022
    
    ✓ 
    Drug product
  
  
  
  • July 25, 2022
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Methods for inhibiting sterol absorption
  Patent 7,612,058
  Issued: November 3, 2009
  Inventor(s): Cho; Wing-Kee Philip
  Assignee(s): Schering Corporation
  The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.
  
  Patent expiration dates:
  
  
  • January 25, 2022
    
    ✓ 
    Patent use: REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL
  
  
  
  • January 25, 2022
    
    ✓ 
    Patent use: TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE
  
  
  
  • July 25, 2022
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
  Patent RE37721
  Issued: May 28, 2002
  Inventor(s): Stuart B.; Rosenblum & Sundeep; Dugar & Duane A.; Burnett & John W.; Clader & Brian A.; McKittrick
  Assignee(s): Schering Corporation
  Hydroxy-substituted azetidinone hypocholesterolemic agents of the formula or a pharmaceutically acceptable salt thereof, wherein: Ar1 and Ar2 are aryl or R4-substituted aryl; Ar3 is aryl or R5-substituted aryl; X, Y and Z are —CH2—, —CH(lower alkyl)— or —C(dilower alkyl)—; R and R2 are —OR6, —O(CO)R6, —O(CO)OR9 or —O(CO)NR6R7; R1 and R3 are H or lower alkyl; q is 0 or 1; r is 0 or 1; m, n and p are 0-4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1-6; and provided that when p is O and r is 1, the sum of m, q and n is 1-5; R4 is selected from lower alkyl, R5, —CF3, —CN, —NO2 and halogen R5 is selected from —OR6, —O(CO)R6, —O(CO)OR9, —O(CH2)1-5OR6, —O(CO)NR6R7, —NR6R7, —NR6(CO)R7, —NR6(CO)OR9, —NR6(CO)NR7R8, —NR6SO2R9, —COOR6, —CONR6R7, —COR6, —SO2NR6R7, S(O)0-2R9, —O(CH2)1-10—COOR6, —O(CH2)1-10CONR6R7, —(lower alkylene)COOR6 and —CH═CH—COOR6; R6, R7 and R8 are H, lower alkyl or aryl-substituted Ic R9 is lower alkyl, aryl or aryl-substituted lower alkyl; are disclosed, as well as a method of lowering serum cholesterol by administering said compounds, alone or in combination with a cholesterol biosynthesis inhibitor, pharmaceutical compositions containing them; and a process for preparing them.
  
  Patent expiration dates:
  
  
  • October 25, 2016
    
    ✓ 
    Patent use: TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • April 25, 2017
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
  Patent RE42461
  Issued: June 14, 2011
  Inventor(s): Rosenblum; Stuart B. & Dugar; Sundeep & Burnett; Duane A. & Clader; John W. & McKittrick; Brian A.
  Assignee(s): Schering Corporation
  Hydroxy-substituted azetidinone hypocholesterolemic agents of the formula or a pharmaceutically acceptable salt thereof, wherein: Ar1 and Ar2 are aryl or R4-substituted aryl; Ar3 is aryl or R5-substituted aryl; X, Y and Z are —CH2—, —CH(lower alkyl)— or —C(dilower alkyl)—; R and R2 are —OR6, —O(CO)R6, —O(CO)OR9 or —O(CO)NR6R7; R1 and R3 are H or lower alkyl; q is 0 or 1; r is 0 or 1; m, n and p are 0-4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1-6; and provided that when p is O and r is 1, the sum of m, q and n is 1-5; R4 is selected from lower alkyl, R5, —CF3, —CN, —NO2 and halogen R5 is selected from —OR6, —O(CO)R6, —O(CO)OR9, —O(CH2)1-5OR6, —O(CO)NR6R7, —NR6R7, —NR6(CO)R7, —NR6(CO)OR9, —NR6(CO)NR7R8, —NR6SO2R9, —COOR6, —CONR6R7, —COR6, —SO2NR6R7, S(O)0-2R9, —O(CH2)1-10—COOR6, —O(CH2)1-10CON6R7, —(lower alkylene)COOR6 and —CH═CH—COOR6; R6, R7 and R8 are H, lower alkyl or aryl-substituted Ic R9 is lower alkyl, aryl or aryl-substituted lower alkyl; are disclosed, as well as a method of lowering serum cholesterol by administering said compounds, alone or in combination with a cholesterol biosynthesis inhibitor, pharmaceutical compositions containing them; and a process for preparing them.
  
  Patent expiration dates:
  
  
  • October 25, 2016
    
    ✓ 
    Patent use: TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • October 25, 2016
    
    ✓ 
    Patent use: TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • April 25, 2017
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • June 5, 2011 - INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL
  
  
  • December 5, 2011 - PEDIATRIC EXCLUSIVITY
  
  
  • January 24, 2015 - CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
  
  

See also...

• Zetia Consumer Information (Drugs.com)
• Zetia Consumer Information (Wolters Kluwer)
• Zetia Consumer Information (Cerner Multum)
• Zetia Advanced Consumer Information (Micromedex)
• Zetia AHFS DI Monographs (ASHP)
• Ezetimibe Consumer Information (Drugs.com)
• Ezetimibe Consumer Information (Wolters Kluwer)
• Ezetimibe Consumer Information (Cerner Multum)
• Ezetimibe Advanced Consumer Information (Micromedex)
• Ezetimibe AHFS DI Monographs (ASHP)

Vincristin-Teva

Vincristin-Teva may be available in the countries listed below.

Ingredient matches for Vincristin-Teva

Vincristine

Vincristine sulfate (a derivative of Vincristine) is reported as an ingredient of Vincristin-Teva in the following countries:

• Czech Republic


• Slovakia


• Switzerland

International Drug Name Search